Iovance Biotherapeutics (IOVA) AI Stock Analysis

• Market Cap: $658.57M
• Dividend Yield: N/A
• Average Volume (3M): 13.03M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.18
• Revenue Growth: 636.99%
• EPS Growth: 27.10%
• Country: US
• Employees: 838
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.25
• Shares Outstanding: 361,853,880
• 10 Day Avg. Volume: 16,506,588
• 30 Day Avg. Volume: 13,027,757
• PEG Ratio: 0.18
• Price to Book (P/B): 3.02
• Price to Sales (P/S): 13.07
• P/FCF Ratio: -5.89
• Enterprise Value/Market Cap: 0.50
• Enterprise Value/Revenue: 1.31
• Enterprise Value/Gross Profit: 3.37
• Enterprise Value/Ebitda: -0.90
• 1Y Price Target: $11.75
• Price Target Upside: 408.66% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $2.00 ▼(-13.42% Downside)

Iovance Biotherapeutics' overall stock score is primarily impacted by its weak financial performance, characterized by ongoing losses and cash flow challenges. While the earnings call provided some positive insights into revenue growth and strategic initiatives, the technical analysis and valuation remain concerning. The company's ability to manage expenses and expand globally will be crucial for future performance.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong demand for Iovance's products and successful strategic initiatives, supporting long-term business sustainability.

Strategic Restructuring

Improved margins from strategic restructuring enhance profitability, indicating effective management and potential for sustained financial health.

Positive Clinical Data

Promising clinical data in lung cancer enhances Iovance's market position and potential for future product approvals, driving long-term growth.

Negative Factors

Profitability Challenges

Ongoing profitability issues highlight operational inefficiencies, posing risks to long-term financial stability and necessitating cost management improvements.

Cash Flow Constraints

Cash flow challenges limit Iovance's ability to invest in growth opportunities and may impact its financial flexibility over the long term.

Global Market Expansion Challenges

Delays in international market approvals could hinder revenue diversification and growth, affecting Iovance's global market penetration strategy.

Iovance Biotherapeutics Business Overview & Revenue Model

Company Description

Iovance Biotherapeutics (IOVA) is a clinical-stage biotechnology company focused on developing innovative cell therapies for cancer treatment. The company specializes in tumor-infiltrating lymphocyte (TIL) therapy, an approach that harnesses the body's immune system to target and destroy cancer cells. Iovance is primarily engaged in the research, development, and commercialization of its lead product candidate, Lifileucel, which is designed for the treatment of metastatic melanoma and other solid tumors. The company operates in the biopharmaceutical sector, aiming to provide effective therapeutic options to patients with challenging cancers.

How the Company Makes Money

Iovance Biotherapeutics generates revenue primarily through the development and commercialization of its cell therapy products. The company may earn revenue from product sales once its therapies receive regulatory approval and enter the market. Additionally, Iovance may engage in strategic partnerships and collaborations with larger pharmaceutical companies, which can provide upfront payments, milestone payments upon achieving specific development goals, and royalties on future sales of the therapies developed under these agreements. These partnerships not only enhance Iovance's financial resources but also facilitate the advancement of its product candidates through clinical trials and regulatory processes. Research grants and funding from government or non-profit organizations may also contribute to the company's revenue streams, particularly during the development stages of its therapies.

Iovance Biotherapeutics Financial Statement Overview

Summary

Iovance Biotherapeutics is experiencing revenue growth but faces significant profitability and cash flow challenges. The company maintains a low leverage position, which is positive, but the negative return on equity and cash flow issues highlight the need for improved operational efficiency and cost management. Overall, the financial health of the company is weak, with potential risks due to ongoing losses and cash flow constraints.

Income Statement

Iovance Biotherapeutics shows a positive revenue growth rate of 13.56% in the TTM, indicating some progress in revenue generation. However, the company is struggling with profitability, as evidenced by negative net profit, EBIT, and EBITDA margins. The gross profit margin has decreased compared to the previous year, reflecting challenges in maintaining cost efficiency.

Balance Sheet

The company's debt-to-equity ratio is relatively low at 0.076, suggesting a conservative leverage position. However, the return on equity is negative, indicating that the company is not generating profits from its equity base. The equity ratio is not explicitly calculated, but the company maintains a substantial equity base relative to its assets.

Cash Flow

Iovance Biotherapeutics has a negative operating cash flow and free cash flow, with a slight decline in free cash flow growth. The operating cash flow to net income ratio is negative, indicating cash flow challenges. However, the free cash flow to net income ratio is slightly above 1, suggesting that free cash flow is somewhat aligned with net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	250.43M	164.07M	1.19M	0.00	0.00	0.00
Gross Profit	97.07M	40.08M	-9.57M	-21.14M	-13.98M	-8.71M
EBITDA	-363.50M	-351.67M	-427.43M	-374.76M	-328.27M	-250.87M
Net Income	-397.63M	-372.18M	-444.04M	-395.89M	-342.25M	-259.58M
Balance Sheet
Total Assets	904.95M	910.43M	780.35M	663.98M	777.33M	768.46M
Cash, Cash Equivalents and Short-Term Investments	300.80M	323.78M	279.87M	471.85M	504.41M	629.44M
Total Debt	51.49M	58.26M	75.86M	85.45M	71.53M	51.66M
Total Liabilities	202.66M	200.02M	195.74M	164.34M	155.67M	111.96M
Stockholders Equity	702.29M	710.40M	584.61M	499.64M	621.66M	656.50M
Cash Flow
Free Cash Flow	-351.82M	-364.05M	-384.11M	-313.18M	-265.51M	-251.93M
Operating Cash Flow	-323.14M	-352.98M	-361.82M	-292.76M	-227.94M	-205.13M
Investing Cash Flow	70.40M	-96.41M	-155.24M	256.45M	132.00K	-317.85M
Financing Cash Flow	246.91M	390.66M	462.96M	190.15M	239.27M	576.42M

Iovance Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.31
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IOVA, the sentiment is Positive. The current price of 2.31 is above the 20-day moving average (MA) of 2.13, above the 50-day MA of 2.19, and below the 200-day MA of 2.94, indicating a neutral trend. The MACD of -0.06 indicates Positive momentum. The RSI at 56.85 is Neutral, neither overbought nor oversold. The STOCH value of 28.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IOVA.

Iovance Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IMTX	48 Neutral	$1.09B	―	-17.34%	―	83.36%	22.27%
AMLX	47 Neutral	$1.47B	―	-87.42%	―	-100.08%	-2.45%
IOVA	45 Neutral	$658.57M	―	-53.16%	―	636.99%	27.10%
KALV	45 Neutral	$543.63M	―	-190.18%	―	―	-13.14%
NUVB	45 Neutral	$1.66B	―	-52.49%	―	1137.19%	70.51%
VIR	42 Neutral	$729.31M	―	-49.06%	―	-78.55%	7.74%

Iovance Biotherapeutics Corporate Events

Iovance Biotherapeutics Advances in Endometrial Cancer Treatment with Lifileucel Study

Study Overview: Iovance Biotherapeutics is conducting a Phase 2 study titled ‘A Phase 2, Multicenter, Open-label Study of Lifileucel (Tumor-infiltrating Lymphocytes [TIL]) in Participants With Previously Treated Advanced Endometrial Cancer.’ The study aims to assess the efficacy and safety of the lifileucel regimen in patients with advanced endometrial cancer who have undergone prior treatments. This research is significant as it explores a potential new treatment avenue for a challenging cancer type.

Iovance Biotherapeutics’ Phase 3 Study: A Potential Game-Changer in Melanoma Treatment

Study Overview: Iovance Biotherapeutics is conducting a Phase 3 clinical study titled A Phase 3, Multicenter, Randomized, Open-label, Parallel Group, Treatment Study to Assess the Efficacy and Safety of the Lifileucel (LN-144, Autologous Tumor Infiltrating Lymphocytes [TIL]) Regimen in Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy in Participants With Untreated, Unresectable or Metastatic Melanoma. The study aims to evaluate the effectiveness and safety of combining lifileucel with pembrolizumab versus using pembrolizumab alone in treating advanced melanoma, a significant concern due to its aggressive nature and limited treatment options.

Iovance Biotherapeutics Advances TIL Therapy in Pediatric Cancer Study

Iovance Biotherapeutics is conducting a Phase 1 clinical study titled A Phase 1, Multicenter, Open-label, 2-stage, Single-arm Study to Evaluate the Safety and Tolerability of an Autologous Tumor-infiltrating Lymphocytes (TIL) Regimen and Preliminary Antitumor Activity of TIL in Pediatric, Adolescent, and Young Adult Participants With Relapsed or Refractory Solid Tumors. The study aims to assess the safety and effectiveness of TIL therapy in young patients with solid tumors that have relapsed or are unresponsive to standard treatments.

Iovance Biotherapeutics’ Promising Phase 2 Study on LN-145 for Lung Cancer

Study Overview: Iovance Biotherapeutics is conducting a Phase 2 multicenter study titled ‘A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer.’ The study aims to evaluate the efficacy of LN-145, a treatment for patients with metastatic non-small-cell lung cancer, highlighting its potential significance in advancing cancer therapy.

Iovance Biotherapeutics’ Innovative Cancer Study: A Potential Game-Changer?

Study Overview: Iovance Biotherapeutics is conducting a Phase 2 study titled A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors. The study aims to evaluate the effectiveness of adoptive cell therapy using tumor infiltrating lymphocytes (TIL) in combination with immune checkpoint inhibitors or as a standalone treatment for various solid tumors, including metastatic melanoma, head and neck squamous cell carcinoma, and non-small cell lung cancer. This study is significant as it explores innovative cancer treatments that could potentially improve patient outcomes.

Iovance Biotherapeutics Advances Melanoma Treatment with New Study

Study Overview: Iovance Biotherapeutics is conducting a Phase 1/2 study titled ‘A Phase 1/2, Open-label Study of a Modified Interleukin-2 Fusion Protein (IOV-3001) in Participants With Previously Treated, Unresectable or Metastatic Melanoma Who Will Receive Lifileucel.’ The study aims to evaluate the safety and efficacy of IOV-3001 in adults with advanced melanoma, focusing on those who have previously undergone treatment. This research is significant as it explores new therapeutic options for melanoma patients with limited treatment alternatives.

Iovance Biotherapeutics Advances Cancer Treatment with IOV-4001 Study Update

Study Overview: Iovance Biotherapeutics is conducting a Phase 1/2 study titled ‘A Phase 1/2, Open-label Study of PD-1 Knockout Tumor-infiltrating Lymphocytes (IOV-4001) in Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer.’ The study aims to evaluate the efficacy and safety of IOV-4001, a novel treatment for advanced melanoma and non-small-cell lung cancer, highlighting its potential significance in improving patient outcomes in these challenging conditions.

Iovance Biotherapeutics Updates Corporate Presentation

On August 29, 2025, Iovance Biotherapeutics updated its corporate presentation for use at healthcare conferences and with analysts and stockholders. The presentation highlights the company’s progress in TIL therapy, including the commercial launch of products like Amtagvi and Proleukin, and outlines ongoing clinical trials and regulatory submissions, which could impact its market positioning and stakeholder interests.

The most recent analyst rating on (IOVA) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.

Iovance Biotherapeutics Amends Sale Agreement with Jefferies

On August 22, 2025, Iovance Biotherapeutics entered into an Amended and Restated Open Market Sale Agreement with Jefferies LLC for an at-the-market offering program. This agreement allows the company to issue and sell up to $350 million of its common stock, with Jefferies acting as the sales agent. The sale of shares will be conducted under a prospectus supplement to the company’s registration statement, and Jefferies will receive a commission of up to 3% on the gross sales proceeds. This strategic move could enhance Iovance’s financial flexibility and strengthen its market position.

The most recent analyst rating on (IOVA) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.

Iovance Biotherapeutics Gains Health Canada Approval

On August 18, 2025, Iovance Biotherapeutics announced that its product Amtagvi® (lifileucel) received approval from Health Canada for use in advanced melanoma patients who have progressed after anti-PD-1 and targeted therapies. This approval marks Iovance’s first marketing authorization outside the U.S., based on the C-144-01 trial results, and signifies a strategic step in addressing unmet needs in solid tumor cancers, with plans to authorize a Canadian treatment center soon.

The most recent analyst rating on (IOVA) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.

Iovance Biotherapeutics’ Earnings Call Highlights Growth

Iovance Biotherapeutics’ recent earnings call was marked by a generally positive sentiment, driven by strong revenue growth, promising clinical data, and strategic restructuring aimed at cost savings. However, the company also faces challenges, such as increased expenses and the withdrawal of an EMA submission.

Iovance Biotherapeutics Reports Strong Revenue Growth in Q2 2025

Iovance Biotherapeutics, Inc., a biotechnology company, focuses on developing and commercializing novel tumor infiltrating lymphocyte (TIL) therapies for cancer treatment.

Iovance Biotherapeutics Reports Q2 2025 Financial Results

Iovance Biotherapeutics reported its financial results for the second quarter and first half of 2025, highlighting a total product revenue of $60 million in Q2, driven by the U.S. sales of Amtagvi and Proleukin. The company is expanding its market reach with regulatory approvals expected in Canada and other countries, and it continues to advance its TIL cell therapy pipeline with ongoing clinical trials and strategic restructuring to extend its cash runway into the fourth quarter of 2026.

The most recent analyst rating on (IOVA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.

Iovance Biotherapeutics Advances Lifileucel Study for Endometrial Cancer

Study Overview: Iovance Biotherapeutics is conducting a Phase 2 study titled ‘A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.’ The study aims to evaluate the efficacy and safety of the lifileucel regimen in patients with advanced endometrial cancer who have previously undergone treatment with platinum-based chemotherapy and PD-1/PD-L1 inhibitors. This research is significant as it explores a potential new treatment option for a challenging cancer type.